Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
10.90
-1.18 (-9.77%)
At close: Apr 2, 2026, 4:00 PM EDT
10.99
+0.09 (0.83%)
After-hours: Apr 2, 2026, 7:49 PM EDT
Omeros Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
175
Market Cap
784.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 29.87M | -34.96M | -53.93% |
| Dec 31, 2017 | 64.83M | 23.21M | 55.77% |
| Dec 31, 2016 | 41.62M | 28.11M | 208.07% |
| Dec 31, 2015 | 13.51M | 12.97M | 2,406.31% |
| Dec 31, 2014 | 539.00K | -1.06M | -66.31% |
| Dec 31, 2013 | 1.60M | -4.42M | -73.43% |
| Dec 31, 2012 | 6.02M | 1.50M | 33.11% |
| Dec 31, 2011 | 4.52M | 2.42M | 114.92% |
| Dec 31, 2010 | 2.11M | 661.00K | 45.78% |
| Dec 31, 2009 | 1.44M | 274.00K | 23.42% |
| Dec 31, 2008 | 1.17M | -753.00K | -39.16% |
| Dec 31, 2007 | 1.92M | 1.52M | 380.75% |
| Dec 31, 2006 | 400.00K | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.72B |
| Phathom Pharmaceuticals | 175.11M |
| Xencor | 125.58M |
| UroGen Pharma | 109.79M |
| Theravance Biopharma | 107.46M |
| Arbutus Biopharma | 14.08M |
| Janux Therapeutics | 10.00M |
OMER News
- 1 day ago - Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates - Seeking Alpha
- 3 days ago - Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results - Business Wire
- 8 days ago - Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 - Business Wire
- 14 days ago - Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment - Business Wire
- 6 weeks ago - Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program - Business Wire
- 2 months ago - Omeros Announces First Commercial Sales of YARTEMLEA® - Business Wire
- 3 months ago - Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript - Seeking Alpha